The acquisition will strengthen the company’s leadership in the ophthalmic medical devices market and expand its position in the vitreoretinal surgery segment
JENA, Germany, December 16, 2023 /PRNewswire/ — Carl Zeiss Meditec AG announced today that it has entered into an agreement to acquire 100% of the shares of Dutch Ophthalmic Research Center (International) BV (DORC) from investment company Eurazeo SE, Paris, France. The acquisition will enhance and complement ZEISS Medical Technology’s extensive ophthalmic portfolio and range of digitally connected workflow solutions to treat a wide variety of eye diseases, including retinal disorders, cataracts, glaucoma and vision errors. refraction.
DORC, a major player in the retinal surgical device market, will be a key contributor to the long-term strategy and future success of ZEISS Medical Technology. With this acquisition, ZEISS will expand its position in the vitreoretinal (VR) surgery segment, strengthening its position as the fastest growing ophthalmic medical device manufacturer in the world. DORC products are used by eye surgeons around the world to treat a wide range of vision-threatening conditions. Their innovative range of devices, disposables and fluids for ophthalmic surgeries provides a strong complement to ZEISS’s medical technology portfolio.
DORC also brings to the acquisition one of the most advanced dual-function systems on the market: the EVA NEXUS™ platform. EVA NEXUS™ is at the heart of a robust portfolio, comprising a dual capacity system and a comprehensive range of accessories, instruments and fluids providing a best-in-class solution for VR, cataract and combined procedures, ensuring surgeons that they can rely on a single platform to address a variety of procedure types.
“With the acquisition of the Dutch Ophthalmic Research Center, we will bring together two highly innovative ophthalmic powerhouses to accelerate ZEISS’s position in the vitreoretinal surgery segment and expand our leadership in the ophthalmic medical device market,” says Dr. Marc WeberPresident and Managing Director of Carl Zeiss Meditec AG.
“Meeting the growing surgical needs of our customers to improve patients’ lives is the cornerstone of this acquisition,” says Euan S. Thomson, Ph.D., Head of Ophthalmology Strategic Business Unit and Head of Digital Business Unit for ZEISS Medical Technology. “By joining forces with the Dutch Ophthalmic Research Center, we will significantly enhance our ZEISS Retina workflow and overall portfolios for the posterior and anterior surgery segments, helping to firmly establish our position as a leading solutions provider in the global market retinal surgery.
“In the year that DORC celebrates 40 years of innovation in ophthalmic surgery, we couldn’t be more excited to join a market leader and visionary like ZEISS Medical Technology,” said Pierre Billardon, CEO of the Dutch Ophthalmic Research Center, International. “We have built an incredible business with innovative, market-leading products and we look forward to seizing this growth opportunity and advancing the future of ophthalmic surgery.” I am personally proud and immensely grateful to the entire DORC team for their commitment and expertise in helping patients see again.
The acquisition is valued at approximately EUR 985 million and is expected to be completed in the first half of calendar year 2024. The transaction remains subject to applicable regulatory and antitrust approvals. RBC Capital Markets acted as exclusive financial advisor on the transaction.
Not all products, services or offerings are approved or offered in all markets and approved labeling and instructions may vary by country. For country-specific product information, visit the respective country’s website. Product specifications are subject to change in design and scope of delivery due to continuous technical development..
Contact for investors:
Sébastien Frericks
Director Investor Relations
Carl Zeiss Meditec SA
Telephone: +49 3641 220 116
Email: investors.meditec@zeiss.com
Press contact:
Jörg Nitschke
Responsible for corporate branding, communications and public affairs
ZEISS Group
+49 7364 20-3242
Email: joerg.nitschke@zeiss.com
Frank E. Smith
Head of Global Communications, ZEISS Ophthalmology
Carl Zeiss Meditec
Telephone: +1 925 487 3036
Email: frank.smith@zeiss.com
Company profiles:
Carl Zeiss Meditec SA
Carl Zeiss Meditec AG (ISIN: DE0005313704), listed on the MDAX and TecDAX of the German Stock Exchange, is one of the world’s leading medical technology companies. The company provides innovative technologies and application-oriented solutions designed to help physicians improve the quality of life of their patients. The company offers comprehensive solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated a turnover of €2,089.3 million during the 2022/23 financial year (as of September 30).
The Group’s head office is located in Jena, Germanyand it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the UNITED STATES, Japan, Spain And France. The Application and Research Center (CARIn) of Bangalore, India and the Carl Zeiss Innovation Center for Research and Development at Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 41 percent of the shares of Carl Zeiss Meditec AG are free float. The rest approx. 59 percent is owned by Carl Zeiss AG, one of the world’s leading groups in the optics and optoelectronics sectors.
For more information, visit: www.zeiss.com/med
About DORC Dutch Ophthalmic Research Center (International) BV
DORC is one of the world’s leading suppliers of equipment, instruments and fluids for ophthalmic surgery. For 40 years, DORC has grown into a successful international company, shaping its product portfolio through close collaboration with leading surgeons. The company improves eye surgery globally and optimizes surgeon control by delivering quality, innovative approaches to eye disorders. Its products are exported to more than 80 countries around the world. The company is headquartered in Zuidland, the Netherlandsand has more than 750 employees.
SOURCE Carl Zeiss Meditec AG